Cargando…
Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
Representing 15% to 20% of all invasive breast cancers, adjuvant systemic treatment for early-stage, high-risk triple-negative breast cancer (TNBC) is preferentially done in the neoadjuvant setting based on a chemotherapy backbone of anthracyclines and taxanes. Pathological complete response to neoa...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243491/ https://www.ncbi.nlm.nih.gov/pubmed/35783596 http://dx.doi.org/10.1177/11782234221107580 |